The Dako 73-10 assay, the fifth PD-L1 US FDA-approved diagnostic test, was co-developed and commercialized to support the use of avelumab therapy. Clone PD-L1 73-10 is a monoclonal rabbit antibody property of Merck (KGaA, Darmstadt, Germany) optimized to detect PD-L1 expression in FFPE samples. Although a cutoff has not been definitely determined, the pre-defined PD-L1 positivity is considered when a complete circumferential or partial linear plasma membrane staining is observed at any intensity in at least 1% of tumor cells. Since this assay is still in development, the minimum of viable tumor cells required to determine the TPS is still undefined.
Non Small Cell Lung Cancer
PD-L1 (Programmed death ligand 1)
Bavencio (avelumab)
Immunohistochemistry (IHC)